arrow
T

Tatsuya Yoshida

National Cancer Center Hospital
H指数:32
被引数:7,713

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Comprehensive Genomic Profiling Beyond Driver Testing in Non-Squamous Non-Small Cell Lung Cancer With Known Drivers

已知驱动基因的非鳞非小细胞肺癌中,超越驱动基因检测的全面基因组分析

2026-09-230
OA
Tarlatamab in small cell lung cancer following platinum-based chemotherapy: subgroup analysis of Japanese patients from the DeLLphi-304 study

塔拉他马布在铂类化疗后的小细胞肺癌中的应用:DeLLphi-304研究中日本患者的亚组分析

2026-09-190
OAAI
Patient-reported outcomes with tarlatamab in extensive-stage small cell lung cancer after platinum-based chemotherapy: results from the phase 3 DeLLphi-304 trial

在铂类化疗后广泛期小细胞肺癌中使用塔拉他玛单抗的病人报告结局:DeLLphi-304 III期试验结果

2026-09-010
PRE
Clinical outcomes and genomic features of uncommon EGFR exon 19 deletion subtypes in osimertinib-treated non-small cell lung cancer

奥希替尼治疗非小细胞肺癌中少见EGFR外显子19缺失亚型的临床结局与基因组特征

2026-08-310
PRE
Role of VEGFA/VEGFR2 signaling in predicting clinical outcomes of EGFR-TKI treatment in EGFR-mutant non-small cell lung cancer

VEGFA/VEGFR2信号在预测EGFR突变非小细胞肺癌EGFR-TKI治疗临床结局中的作用

2026-06-020
PRE
Comparative analysis of therapeutic target protein expression in de novo and transformed small cell lung carcinomas using paired biopsy samples

使用配对活检样本对原发性和转化型小细胞肺癌的 therapeutic target protein 表达进行对比分析

2026-04-170
PRE
Four-Year Outcomes for Nivolumab With Chemotherapy and Bevacizumab in Patients With Nonsquamous NSCLC in the TASUKI-52

Nivolumab联合化疗和贝伐单抗治疗TASUKI-52非鳞NSCLC患者的4年预后

2026-01-290
OAAI
Risk-reducing mastectomy and salpingo-oophorectomy in women with hereditary breast and ovarian cancer: a single-institute experience following coverage by Japanese national medical insurance

遗传性乳腺癌和卵巢癌女性患者中的风险降低性乳房切除术和输卵管卵巢切除术:一项基于日本国民健康保险覆盖后的单机构经验

2025-12-010
PRE
Chromosome 15q15 Deletion Drives Brain Metastasis in Non-Small Cell Lung Cancer

染色体15q15缺失驱动非小细胞肺癌脑转移

2025-11-070
PRE
Mutation of CMTR2 in Lung Adenocarcinoma Alters RNA Alternative Splicing and Reveals Therapeutic Vulnerabilities

CMTR2基因突变在肺腺癌中改变了RNA选择性剪接并揭示了治疗易感性

2025-11-060
OAAI
Genomic profiles of pathogenic and moderate-penetrance germline variants associated with risk of early-onset lung adenocarcinoma

与早发性肺腺癌风险相关的致病性和中等外显率生殖细胞系变异的基因组特征

2025-06-150
OAAI
First-line nivolumab plus platinum chemotherapy and bevacizumab for advanced nonsquamous non-small cell lung cancer: A 3-year follow-up of the phase 3 randomized TASUKI-52 trial

一线纳武利尤单抗联合铂类化疗和贝伐珠单抗治疗晚期非鳞非小细胞肺癌:TASUKI-52 III期随机试验3年随访

2025-03-010
PRE